Survival rates of cancer patients with and without rheumatic disease: a retrospective cohort analysis.
Survival rates of cancer patients with and without rheumatic disease: a retrospective cohort analysis.
复制标题
DOI：
10.1186/s12885-016-2444-5
复制
发表时间：
2016-07-04
期刊：
影响因子：
3.8
通讯作者：
Lee EB
中科院分区：
文献类型：
--
作者：
Park JK;Yang JA;Ahn EY;Chang SH;Song YW;Curtis JR;Lee EB
比较伴有和不伴有风湿性疾病（RD）的胃癌、结肠癌、肺癌和乳腺癌患者的结局。这项回顾性研究比较了122例患有类风湿性关节炎（RA）、系统性红斑狼疮（SLE）、皮肌炎/多发性肌炎（DM/PM）或系统性硬化症的癌症患者队列与366例年龄、性别和癌症类型匹配的无RD患者队列的癌症生存率，这些患者在2000年至2014年期间接受了医疗护理。确定分期、合并症和功能状态。使用Kaplan-Meier方法比较生存率。使用考克斯回归分析，以风险比（HR）估计相对死亡风险。RD患者在癌症诊断时的平均年龄为58.7 ± 11.5岁。胃癌患者的总生存率在队列之间没有差异。RA或DM/PM患者的肺癌或乳腺癌生存率低于无RD患者（均P < 0.05）。校正癌症分期、合并症指数、体能状态和癌症诊断时的年龄后（以及肺癌组的间质性肺疾病），肺癌患者中RA的死亡率明显高于（HR，1.81; 95%CI，1.03-3.18），而SSc与肺癌死亡率降低有关（HR，0.16; 95% CI，0.04-0.58）。DM/PM与乳腺癌患者死亡率增加相关（HR，297.39; 95%CI，4.24-20842.33）。RA和DM/PM似乎与肺癌或乳腺癌患者的较高死亡率相关，而SSc似乎与肺癌患者的死亡率降低相关。有必要根据特定的RD探索定制化癌症治疗的生存效果。本文的在线版本（doi：10.1186/s12885-016-2444-5）包含补充材料，可供授权用户使用。
To compare the outcomes of gastric, colon, lung, and breast cancer patients with and without rheumatic diseases (RD). This retrospective study compared the cancer survival rates of a cohort of 122 cancer patients with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), dermatomyositis/polymyositis (DM/PM), or systemic sclerosis with that of a cohort of 366 age-, sex-, and, cancer type-matched patients without RD who received medical care from 2000 to 2014. Staging, comorbidities, and functional status were ascertained. Survival was compared using the Kaplan-Meier method. Relative risk of death was estimated as a hazard ratio (HR) using Cox regression analysis. The mean age of the RD patients at the time of cancer diagnosis was 58.7 ± 11.5 years. The overall survival rate of gastric cancer patients did not differ between the cohorts. The survival of lung or breast cancer was worse in patients with RA or DM/PM than in those without RD (all, p < 0.05). After adjusting for cancer stage, comorbidity index, performance status and age at the time of cancer diagnosis (as well as interstitial lung disease for lung cancer group), the mortality rate among lung cancer patients with RA was significantly higher (HR, 1.81; 95 % CI, 1.03–3.18) than that of lung cancer patients without RD, whereas SSc was associated with decreased mortality of lung cancer (HR, 0.16; 95 % CI, 0.04–0.58). DM/PM were associated with increased mortality of breast cancer patients (HR, 297.39; 95 % CI, 4.24–20842.33). RA and DM/PM seemed to be associated with a higher mortality in patients with lung or breast cancers, whereas SSc seemed to be associated with decreased mortality in patients with lung cancer. It is warranted to explore the survival effect of tailored cancer treatments according to specific RD. The online version of this article (doi:10.1186/s12885-016-2444-5) contains supplementary material, which is available to authorized users.